Catalyst Event
Hansoh Pharmaceutical Group Company Limited (3692) · Other
From Akros SCHK HK-US Biotech Index (ASHUBIO)
3/27/2026, 12:00:00 AM
Received drug registration approval from China's NMPA on 2026-03-27 for the third indication of Xinyue®; Medium importance estimated as new indications drive growth expected.
Korean Translation
2026-03-27에 중국 국가약품감독관리국(NMPA)으로부터 신위에®의 세 번째 적응증 허가를 취득함. 신규 적응증 추가에 따른 시장 확대가 예상되어 중간 수준의 중요도로 예상됨.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM